Transient elastography (FibroScan®) is widely used for non-invasive assessment of liver stiffness, with established reference values derived from heterogeneous liver disease populations.
These reference values are currently applied to individuals with AATD, despite their unique disease mechanism. It is therefore plausible that normal or reference FibroScan values may be higher in individuals with AATD who have no clinical or biochemical evidence of liver disease.
The lack of AATD-specific reference values may lead to misclassification and unnecessary referral to specialist hepatology care. Establishing AATD-specific reference values for FibroScan may improve risk stratification, reduce unnecessary hepatology referrals, and support broader involvement of non-hepatology clinicians in the monitoring of liver disease in individuals with severe AATD.